---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-005780"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T19:49:06.490631+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oramed forms JV with HTIT for oral insulin; HTIT contributes $70M, Oramed $20M + IP

## Summary
- Joint venture will develop oral insulin and POD technology; HTIT contributes $70M cash, Oramed $10M cash + $10M in ORMP shares.
- Oramed transfers intellectual property to JV; receives 3% royalty on gross revenues from Oramed-related assets.
- JV intends to initiate a Phase 3 oral insulin trial in the United States.
- Closing contingent on signing ancillary agreements within 3 months and obtaining IIA approval (estimated redemption fee $2M-$6M).
- Initially 50/50 ownership; HTIT has option to invest up to $20M more for increased equity stake.

## SEC filing metadata
- accession: 0001213900-24-005780
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390024005780/0001213900-24-005780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390024005780/ea192032-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-005780
- JSON: https://secwatch.observer/filing/0001213900-24-005780.json
- Plain text: https://secwatch.observer/filing/0001213900-24-005780.txt

## Key facts
- Material Agreements
  ORAMED PHARMACEUTICALS INC. entered into "JV Agreement" with Hefei Tianhui Biotech Co., Ltd. and Technowl Limited valued at $70 million in cash from HTIT and $20 million from Oramed (comprised of $10 million in cash and $10 (effective 2024-01-22).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Hefei Tianhui Biotech Co., Ltd. and Technowl Limited
  - Value: $70 million in cash from HTIT and $20 million from Oramed (comprised of $10 million in cash and $10
  - Effective: 2024-01-22
  source text: On January 22, 2024, Oramed Pharmaceuticals Inc., a Delaware corporation (“Oramed”) and its wholly-owned subsidiary, Oramed Ltd., entered into a Joint Venture Agreement (the “JV Agreement”) with Hefei Tianhui Biotech Co., Ltd. (“HTIT Biotech”) and Technowl Limited, a wholly-owned indirect subsidiary of HTIT Biotech (“HTIT Sub,” and together with HTIT Biotech, “HTIT”), pursuant to which, subject to the terms and conditions set forth in the JV Agreement, the parties will establish a joint venture (“JV”) based on Oramed’s oral drug delivery technology.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1176309/000121390024005780/0001213900-24-005780-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.